View Post

Startup joins Roche to hold clinical trials for double-whammy cancer drug

In Clinical Trials by Barbara Jacoby

By: Shoshanna Solomon From: imesofisrael.com DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them KAHR Medical, an Israeli biopharmaceutical company, says it is developing a second generation class of  immunotherapy drugs that it hopes will be more effective in tackling cancer, based on the lessons learned …

View Post

Diverse immune cell profiles and roles found in breast cancer resistance to immunotherapy

In In The News by Barbara Jacoby

Source: Baylor College of Medicine From: sciencedaily.com Researchers show that heterogeneity of both breast cancer cells themselves and immune composition of the tumor microenvironment are important considerations for therapy.  In recent years it has been increasingly appreciated that immune cells within the tumor microenvironment contribute to tumor progression and, importantly, to the tumor’s response to therapy. To better understand the …

View Post

AI reveals new breast cancer types that respond differently to treatment

In In The News by Barbara Jacoby

By: Institute of Cancer Research From: medicalxpress.com Scientists have used artificial intelligence to recognise patterns in breast cancer—and uncovered five new types of the disease each matched to different personalised treatments. Their study applied AI and machine learning to gene sequences and molecular data from breast tumours, to reveal crucial differences among cancers that had previously been lumped into one …

View Post

Where Cancer-killing T-cells Come From

In In The News by Barbara Jacoby

By: Shirley Dang From: parkerici.org New research published today in Nature Medicine by scientists from the Stanford University School of Medicine and the Parker Institute for Cancer Immunotherapy sheds new light on the origins of tumor-fighting immune cells following immunotherapy treatment with anti-PD-1 checkpoint inhibitors. Using single-cell RNA sequencing technology, the group discovered that T-cells homing in on cancer did …

View Post

Immunotherapy for lung cancer: Researchers working to broaden its reach

In Clinical Trials by Barbara Jacoby

By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …

View Post

The Problem With Miracle Cancer Cures

In In The News by Barbara Jacoby

By: Robert M. Wachter From: nytimes.com I FREQUENTLY care for patients with advanced cancer. A majority have already tried some combination of surgery, chemotherapy and radiation. Many have landed back in the hospital because the cancer has returned or spread widely and left them in intractable pain or struggling to breathe. The hospital stay is often a time when patients …

View Post

Immunotherapy combination effective for patients with rare neuroendocrine cancer

In Clinical Trials by Barbara Jacoby

Source: SWOG From: eurekalert.org A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta. Results from the SWOG Cancer Research Network trial known as DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, show …

View Post

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: apnews.com CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the …

View Post

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

In Clinical Trials by Barbara Jacoby

Provider: Business Wire From: apnews.com Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “ Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta. The discussion …